The UK and US have hammered out a important commercial pact that will maintain no import taxes on UK pharmaceutical products being sold in the American market.
The Terms of the Deal
As part of the deal, the UK has agreed to boost expenditure on drugs through the NHS. This commitment ensures that import taxes on these key products will stay at nothing for a timeframe of the next three years.
This development is in response to recent statements to hike import taxes on patented pharmaceutical imports, with figures discussed as high as 100%.
"This agreement with the Britain strengthens the worldwide climate for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. pharmaceutical trade," an announcement declared.
Commercial Significance
Medicines represent one of the UK's biggest goods shipped to the US, which is clearly the largest buyer for leading UK drugmakers.
Trade data show that in the 12 months leading up to the third quarter, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This amount made up nearly one-fifth of all goods exports in that span.
"This guarantee safeguards jobs, increases investment and paves the way for the UK to establish itself as a global hub for life sciences," a government official stated.
Detailed NHS Changes
The pact includes several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to double overall health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, repayments exceeded twenty percent.
Recent Tensions
The deal comes amid a protracted dispute between the sector and the UK government over medicine costs and NHS adoption.
These tensions were intensified by claims that US consumers were charged significantly more for the equivalent treatments than patients in the UK and Europe.
Recently, several major manufacturing plans in the UK have been halted or cancelled, while major investments have been announced toward American operations.
One official publicly accepted that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had declined as a share of its overall budget over the past decade.
